September 17, 2018 08:42 AM EDT
Pharma

CRISPR pays to part­ner with Vi­a­Cyte on an off-the-shelf gene-edit­ing ap­proach to cur­ing di­a­betes

John Carroll

Editor & Founder

Vi­a­Cyte has been de­vel­op­ing a line of pan­cre­at­ic cells out of stem cells, look­ing for a re­gen­er­a­tive med­i­cine ap­proach to treat­ing Type 1 di­a­betes.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times